Stock Events

Stock Events

Vaccinex 

$0.91
17
-$0.11-10.78% Today

Statistics

Day High
0.99
Day Low
0.71
52W High
1.5
52W Low
0.25
Volume
3,529
Avg. Volume
2,690
Mkt Cap
2.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-3,100.5%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.2MRevenue
-37.27MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VCNX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Vaccinex's work on Huntington's disease and Alzheimer's.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, overlapping with Vaccinex's focus on neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a significant focus on Alzheimer's disease, directly competing with Vaccinex's efforts in neurodegenerative disease therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad interest in developing treatments for neurological disorders, making it a competitor in Vaccinex's therapeutic areas.
Novartis
NVS
Mkt Cap237.61B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Vaccinex's research and development focus.
Merck
MRK
Mkt Cap214.76B
Merck is involved in the development of therapies for neurodegenerative diseases, including Alzheimer's, competing with Vaccinex's pipeline.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a strong presence in neuroscience, including R&D in Alzheimer's and Parkinson's, areas of interest for Vaccinex.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on novel therapeutics includes work on neurodegenerative diseases, making it a competitor to Vaccinex.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a broad pipeline that includes neurology, competing with Vaccinex in the development of treatments for neurological disorders.

About

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Show more...
CEO
Dr. Maurice Zauderer Ph.D.
Employees
23
Country
US
ISIN
US9186403013

Listings

OTC Link
US
VCNX

0 Comments

Share your thoughts

FAQ

What is Vaccinex stock price today?▼
The current price of VCNX is $0.91 USD — it has decreased by -10.78% in the past 24 hours. Watch Vaccinex stock price performance more closely on the chart.
What is Vaccinex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaccinex stocks are traded under the ticker VCNX.
Is Vaccinex stock price growing?▼
VCNX stock has fallen by -13.33% compared to the previous week, the month change is a -11.65% fall, over the last year Vaccinex has showed a +29.11% increase.
What is Vaccinex market cap?▼
Today Vaccinex has the market capitalization of 2.44M
When is the next Vaccinex earnings date?▼
Vaccinex is going to release the next earnings report on May 18, 2026.
What is Vaccinex revenue for the last year?▼
Vaccinex revenue for the last year amounts to 1.2M USD.
What is Vaccinex net income for the last year?▼
VCNX net income for the last year is -37.27M USD.
How many employees does Vaccinex have?▼
As of April 01, 2026, the company has 23 employees.
In which sector is Vaccinex located?▼
Vaccinex operates in the Health Care sector.
When did Vaccinex complete a stock split?▼
The last stock split for Vaccinex was on February 20, 2024 with a ratio of 1:14.
Where is Vaccinex headquartered?▼
Vaccinex is headquartered in Rochester, US.